Patents Examined by Deborah C. Lambkin
  • Patent number: 7335782
    Abstract: Photoinitiator compounds of formula (I): {where: A represents a direct bond or a group of formula —[O(CHR7CHR6)a]y—, —[O(CH2)bCO]y—, or —[O(CH2)bCO](y-1)—[O(CHR7CHR6)a]—, where one of R6 and R7 is hydrogen and the other is hydrogen or methyl; a is a number from 1 to 2; b is a number from 4 to 5; Q is a residue of a polyhydroxy compound having 2 to 6 hydroxy groups; x is a number greater than 1 but no greater than the number of available hydroxyl groups in Q; y is a number from 1 to 10; R1, R2, R3 and R4 are individually the same or different and each is hydrogen, hydroxy, or alkyl; or R1 and R3 are joined to form a fused ring system with the benzene rings to which they are attached; and R5 represents a direct bond, an oxygen atom or a methylene group} are useful as cationic photoinitiators, especially for use in surface coating applications, such as printing inks and varnishes, and which are intended to be cured by polymerisation initiated by radiation.
    Type: Grant
    Filed: February 26, 2003
    Date of Patent: February 26, 2008
    Assignee: Sun Chemical Co.
    Inventors: Shaun L. Herlihy, Robert S. Davidson
  • Patent number: 7326726
    Abstract: Biaryl substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof, and a process for making such compounds and salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: February 5, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Prasun K. Chakravarty, Louis L. Zuegner III, legal representative, Brenda Palucki, Min K. Park, William H. Parsons, Bishan Zhou, Michael H. Fisher, deceased
  • Patent number: 7312219
    Abstract: Novel FBPase inhibitors of the formula I and X are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.
    Type: Grant
    Filed: August 6, 2003
    Date of Patent: December 25, 2007
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Qun Dang, Srinivas Rao Kasibhatla, K. Raja Reddy, Mark D. Erion, M. Rami Reddy, Atul Agurwal
  • Patent number: 7294723
    Abstract: Compounds of formula (I): [where: R1 is a direct bond, oxygen, a group >CH2, sulphur, a group >C?O, a group-(CH2)2— or a group-N—Ra, where Ra is hydrogen or alkyl; R3, R4, R5 and R6 are hydrogen or substituents?; R8, R9, R10 and R11 are hydrogen, hydroxy or alkyl; or R9 and R11 are joined to form a fused ring system with the benzene rings to which they are attached; R7 is a direct bond, oxygen or a —CH2-group; p is 0 or 1 ; substituents? are: alkyl, alkoxy, alkenyl, halogen, nitrile, hydroxyl, aryl, aralkyl, aryloxy, aralkyloxy, arylalkenyl, cycloalkyl, carboxy, carboxyalkoxy, alkoxycarbonyl, aryloxycarbonyl, alkylcarbonyloxy, alkanesulphonyl, arenesulphonyl, alkanoyl or arylcarbonyl; n is 1 to 12; R12 is hydrogen, methyl or ethyl; A is a group —[O(CHR13CHR14)a]y—, —[O(CH2)bCO]y-, or —[O(CH2)bCO](y-1)-[O(CHR13CHR14)a]—, where: one of R13 and R14 is hydrogen and the other is hydrogen, methyl or ethyl; a is 1 to 2 ; b is 4 to 5 ; Q is a residue of a polyhydroxy compound having from 2 to 6 hydroxy groups;
    Type: Grant
    Filed: December 10, 2003
    Date of Patent: November 13, 2007
    Assignee: Sun Chemical Corporation
    Inventors: Shaun Lawrence Herlihy, Brian Rowatt, Robert Stephen Davidson
  • Patent number: 7288663
    Abstract: The present invention relates to a process for preparing compounds of the formula (I), where n is an integer from 2 to 5, R1 is H or a C1-C20-alkyl group which may be interrupted by one or more O or S atoms, silylene, phosphonoyl or phosphoryl groups and Ar is substituted or unsubstituted 1,4-phenylene, 2,7-fluorene or 2,5-thiophene, with Ar being able to be identical or different, semiconductive layers comprising these compounds and their use in semiconductor technology.
    Type: Grant
    Filed: October 16, 2003
    Date of Patent: October 30, 2007
    Assignee: H.C. Starck GmbH
    Inventors: Stephen Kirchmeyer, Sergei Ponomarenko
  • Patent number: 7262310
    Abstract: A process for preparing 3-hydroxythiolane which is characterized in reacting a compound of the following formula, wherein X is halogen atom, and R2 is substituted or unsubstituted alkyl group, substituted or unsubstituted aralkyl group, or substituted or unsubstituted aryl group, with a metal sulfide.
    Type: Grant
    Filed: March 29, 2005
    Date of Patent: August 28, 2007
    Assignee: Daiso Co., Ltd.
    Inventors: Kazumasa Hinoue, Masafumi Mikami
  • Patent number: 7250522
    Abstract: The present invention provides a method for preparing an aryl 5-thio-?-D-aldohexopyranoside derivative of Formula (III), which comprises reacting a 5-thio-D-aldohexopyranose derivative of Formula (I) with Ar-OH of Formula (II) in the presence of a phosphine represented by PR11R12R13 and an azo reagent represented by R21—N?N—R22 in accordance with the following scheme
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: July 31, 2007
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Masakazu Sato, Hiroyuki Kakinuma, Hajime Asanuma
  • Patent number: 7244763
    Abstract: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: July 17, 2007
    Assignee: Warner Lambert Company LLC
    Inventors: Larry D. Bratton, Xue-Min Cheng, Noe Erasga, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi, Paul C. Unangst
  • Patent number: 7226943
    Abstract: The present invention relates to compounds of formula (I) wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: June 5, 2007
    Assignee: AstraZeneca AB
    Inventors: Ingemar Starke, Mikael Ulf Johan Dahlstrom, David Blomberg
  • Patent number: 7226940
    Abstract: The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease
    Type: Grant
    Filed: August 24, 2005
    Date of Patent: June 5, 2007
    Assignees: Incyte San Diego, Inc., Ortho McNeil Pharmaceutical Inc.
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul, David P. M. Pleynet, Lyle W. Spruce
  • Patent number: 7220875
    Abstract: The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.
    Type: Grant
    Filed: January 28, 2004
    Date of Patent: May 22, 2007
    Inventors: Mark A. Gallop, Feng Xu, Kenneth C. Cundy, Vivek Susikumar, Thomas W. Woiwode
  • Patent number: 7208495
    Abstract: A compound represented by the formula: (wherein, R1 and R2 are the same or different and each represents a hydrogen atom, hydrocarbon group or heterocyclic group, or R1 and R2 may form, together with the adjacent carbon atom, a 3–8 membered iso- or heterocyclic group, R3 represents a cyclic group, a hydroxy group, a mercapto group that may have oxo, or an amino group, R4 represents a hydrogen atom, a hydrocarbon group, a hydroxy group, a mercapto group which may have oxo, or an amino group, or R2 and R4 may link together to form a double bond, X represents a bond or a linear hydrocarbon group, W represents an oxygen atom or a sulfur atom, ring B represents a 5–8 membered nitrogen-containing heterocyclic group, ring C represents a benzene ring, and— represents a single bond or a double bond), or a salt or a prodrug thereof that has excellent neurodegenerative inhibitory activity and brain penetrability, and is useful as an agent for preventing/treating neurodegenerative diseases.
    Type: Grant
    Filed: July 4, 2002
    Date of Patent: April 24, 2007
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shigenori Ohkawa, Masaomi Miyamoto, Masahiro Okura, Tetsuya Tsukamoto
  • Patent number: 7208610
    Abstract: An improved process and catalyst system for the isomerization of halothiophenes. More particularly, an improved process for the isomerization of 2-halothiopehenes to 3-halothiophenes by reacting a 2-halothiophene with a catalyst and in the presence of a base. The addition of a base additive to the acidic zeolite catalyst allows the desired isomerization reaction to take place while suppressing side-reactions that result in the decomposition of thiophene rings. The catalyst lifetime is thus increased and the amount of catalyst needed for the reaction is reduced, lowering cost.
    Type: Grant
    Filed: January 12, 2005
    Date of Patent: April 24, 2007
    Assignee: Honeywell International Inc.
    Inventors: Christian Werner, Andreas Kanschik-Conradsen, Bernd Kellermeier, Hans-Jürgen Schmidt
  • Patent number: 7208609
    Abstract: The invention relates to a method for producing pure racemic, R- or S-thioctic acid or mixtures thereof by reacting 6,8-disubstituted octanoic acid or their salts or esters with sulfides, sulfur or sulfites.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: April 24, 2007
    Assignee: MEDA Pharma GmbH & Co. KG
    Inventors: Gunter Laban, Peter Meisel, Gilbert Müller
  • Patent number: 7208599
    Abstract: The present invention relates to a process for the preparation of substituted alkanesulfonates by the reaction of an aqueous metal substituted 2-hydroxyethanesulfonate with a nucleophile. 2-Alkylaminoalkanesulfonate is formed when the nucleophile is an amine. The invention also relates to the optimization of reaction conditions to produce an optimum yield.
    Type: Grant
    Filed: October 26, 2004
    Date of Patent: April 24, 2007
    Assignee: Arkema Inc.
    Inventors: Glenn T. Carroll, Gary S. Smith, Gary E. Stringer
  • Patent number: 7206111
    Abstract: In various embodiments, chromophores are described that include novel electron acceptors, novel electron donors, and/or novel conjugated bridges that are useful in nonlinear optical applications. In some embodiments, the present invention provides chromophore architectures wherein a chromophore contains more than one electron acceptor in electronic communication with a single electron donor, and/or more than one electron donor in electronic communication with a single electron acceptor. Also described is processes for providing materials comprising the novel chromophores and polymer matrices containing the novel chromophores. Electro-optic devices described herein contain one or more of the described electron acceptors, electron donors, conjugated bridges, or chromophores.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: April 17, 2007
    Assignee: Lumera Corporation
    Inventors: Diyun Huang, Timothy M. Londergan, Galina K. Todorova, Jingsong Zhu
  • Patent number: 7205414
    Abstract: A method for the formation of 3-alkylthiophenes or 3-arylthiophenes from 3-halothiophenes. More particularly, improvements on the Kumada coupling reaction for the production of 3-alkylthiophenes or 3-arylthiophenes by reacting a 3-halothiophene with an alkylmagnesiumhalide or arylmagnesiumhalide Grignard reagent in the presence of a catalyst and a 2-methyl tetrahydrofuran solvent. The 2-methyl tetrahydrofuran solvent allows for higher concentrations of the Grignard reagent with minimal or no dithienyl side product generation, achieving higher product yields and at a lower cost than other known methods.
    Type: Grant
    Filed: January 12, 2005
    Date of Patent: April 17, 2007
    Assignee: Honeywell International Inc.
    Inventors: Christian Werner, Frauke Platz, Andreas Kanschik-Conradsen
  • Patent number: 7202270
    Abstract: A process for the manufacture of new crystalline salts of N-[2-(dimethylamino)ethyl]-1,2-dithiolane-3-pentanamide (racemic and chiral forms) is described. Such salts are stable, crystalline and have very good solubility in water. The salts exhibit antioxidant properties. They inhibit collagenase and elastase enzymes. They have excellent anti acne activity in addition tyrosinase inhibition. They are, by themselves and in combination with other known agents, important cosmetic ingredients.
    Type: Grant
    Filed: June 15, 2004
    Date of Patent: April 10, 2007
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam
  • Patent number: RE39794
    Abstract: A process is described for the co-production of maleic anhydride and at least one C4 compound selected from butane-1,4-diol, ?-butyrolactone, and tetrahydrofuran in which maleic anhydride is produced by partial oxidation of a hydrocarbon feedstock selected from C4 hydrocarbons and benzene to yield a vaporous reaction effluent stream comprising maleic anhydride, water, unconverted hydrocarbon feedstock, and carbon oxides. A part of the maleic anhydride present in the vaporous reaction effluent stream is condensed to form a crude maleic anhydride stream and leave a residual vaporous stream containing residual amounts of maleic anhydride. Further maleic anhydride is absorbed from the residual vaporous stream by absorption in an organic solvent, water or an aqueous solution. Maleic anhydride is then recovered from the loaded liquid absorptions medium.
    Type: Grant
    Filed: October 4, 2000
    Date of Patent: August 21, 2007
    Assignee: Davy Process Technology Limited
    Inventors: David Mark Sutton, Andrew George Hiles, Adrian Francis Backes
  • Patent number: RE40525
    Abstract: A racemate diastereoisomer and optical isomer of a compound of formula (I): wherein B is H, a C6 or C10 aryl, C7-16 aralkyl; Het or (lower alkyl)-Het, all of which may be optionally substituted with C1-6 alkyl; C1-6 alkoxy; C1-6 alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C1-6 alkyl; amido; or (lower alkyl)amide; or B is an acyl derivative of formula R4—C(O)—; a carboxyl derivative of formula R4—O—C(O)—; an amide derivative of formula R4—N(R5)—C(O)—; a thioamide derivative of formula R4—N(R5)—C(S)—; or a sulfonyl of formula R4—SO2; R5 is H or C1-6 alkyl; and Y is H or C1-6 alkyl; R3 is C1-8 alkyl, C3-7 cycloalkyl, or C4-10 alkylcycloalkyl, all optionally substituted with hydroxy, C1-6 alkoxy, C1-6 thioalkyl, amido, (lower alkyl)amido, C6 or C10 aryl, or C7-16 aralkyl; R2 is C2—R20, NH—R20, O—R20 or S—R20, wherein R20 is a saturated or unsaturated C3-7 cycloalkyl or C4-10 (alkylcycloalkyl), all of which being optionally mono-, di- or tri-
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: September 30, 2008
    Assignee: Boehringer Ingelheim (Canada) Ltd.
    Inventors: Montse Llinas-Brunet, Murray D. Bailey, Dale R. Cameron, Anne-Marie Faucher, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Marc-André Poupart, Jean Rancourt, Youla S. Tsantrizos, Dominik M. Wernic